In this study, we present the synthesis, as well as the enzymatic and biological evaluation of the first class of compounds with dual activity as GSK3β inhibitors and Nrf2 inducers, providing a new therapeutic strategy against AD. Here, NFE2L2 is linked to Alzheimer disease.